New antiepileptic drugs in pediatric epilepsy

Research output: Contribution to journalReview article

31 Citations (Scopus)

Abstract

New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25% of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.

Original languageEnglish
Pages (from-to)549-555
Number of pages7
JournalBrain and Development
Volume30
Issue number9
DOIs
StatePublished - 1 Oct 2008

Fingerprint

Anticonvulsants
Epilepsy
Pediatrics
etiracetam
zonisamide
felbamate
Guidelines
Vigabatrin
Expert Testimony
Therapeutics
Randomized Controlled Trials
Pharmacokinetics
Physicians
Pharmaceutical Preparations

Keywords

  • Antiepileptic drug
  • Evidence-based
  • Pediatric epilepsy

Cite this

@article{a6502adc00914decac7d2e7d02dcc830,
title = "New antiepileptic drugs in pediatric epilepsy",
abstract = "New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25{\%} of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.",
keywords = "Antiepileptic drug, Evidence-based, Pediatric epilepsy",
author = "Hee Hwang and Kijoong Kim",
year = "2008",
month = "10",
day = "1",
doi = "10.1016/j.braindev.2008.01.007",
language = "English",
volume = "30",
pages = "549--555",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "9",

}

New antiepileptic drugs in pediatric epilepsy. / Hwang, Hee; Kim, Kijoong.

In: Brain and Development, Vol. 30, No. 9, 01.10.2008, p. 549-555.

Research output: Contribution to journalReview article

TY - JOUR

T1 - New antiepileptic drugs in pediatric epilepsy

AU - Hwang, Hee

AU - Kim, Kijoong

PY - 2008/10/1

Y1 - 2008/10/1

N2 - New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25% of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.

AB - New antiepileptic drugs (AEDs), introduced since 1993, provide more diverse options in the treatment of epilepsy. Despite the equivalent efficacy and better tolerability of these drugs, more than 25% of patients remain refractory to treatment. Moreover, the issues for pediatric patients are different from those for adults, and have not been addressed in the development and application of the new AEDs. Recently published evidence-based treatment guidelines have helped physicians to choose the most reasonable AED, although they cannot fully endorse new AEDs because of the lack of well-designed, randomized controlled trials. We review the mechanisms of action, pharmacokinetic properties, adverse reactions, efficacy, and tolerability of eight new AEDs (felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, vigabatrin, and zonisamide), focusing on currently available treatment guidelines and expert opinions regarding pediatric epilepsy.

KW - Antiepileptic drug

KW - Evidence-based

KW - Pediatric epilepsy

UR - http://www.scopus.com/inward/record.url?scp=49849105442&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2008.01.007

DO - 10.1016/j.braindev.2008.01.007

M3 - Review article

C2 - 18328657

AN - SCOPUS:49849105442

VL - 30

SP - 549

EP - 555

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 9

ER -